Next-generation sequencing (NGS)-based detection of somatic variants in tumor samples is a powerful tool to uncover the molecular drivers associated with different cancer types. This technology holds promise to enable more accurate prognoses and more effective therapy decisions – the foundation necessary to achieving precision medicine. Using whole-genome, whole-exome, and RNA-Seq, large international projects, such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), have contributed greatly to the catalog of somatic driver mutations that underlie tumorigenesis and progression in many common and rare cancers. These discoveries provide basic research and drug development communities direction to focus on the targets of greatest impact in the war on cancer. In the clinical research and oncology communities, similar sequencing strategies have emerged as a powerful weapon to further understand variation in the clinical course of various cancer types.
These strategies are now accessible to every lab with Illumina’s new NextSeq 500 system. Using a powerful combination of sample preparation, sequencing, and informatics methods, Illumina now enables researchers to perform the same groundbreaking cancer analysis pioneered by groups such as TCGA and ICGC in their labs. This experimental design is more accessible than ever before. Join us to learn how researchers are using this comprehensive approach to continue to discover the biology of cancer and translate discoveries faster than ever before.